grail_editor

Working to Transform Cancer Care Through Early Detection

November 17, 2019

GRAIL Appoints Matthew Young as Chief Operating Officer and Chief Financial Officer

October 7, 2019

GRAIL Announces Positive Validation Data for its Multi-Cancer Early Detection Test

GRAIL Appoints Marissa Song as General Counsel and Corporate Secretary

September 30, 2019

GRAIL to Present New Data in Late-Breaking Oral Presentation at the European Society for Medical Oncology (ESMO) 2019 Congress

September 27, 2019

GRAIL Appoints Rodger Currie as Head of Government Affairs and Alliance Development

August 26, 2019

GRAIL Announces Appointment of Hans Bishop as Chief Executive Officer and Strengthens Leadership Team and Board of Directors with New Appointments

June 6, 2019

GRAIL Announces Positive New Data with Multi-Cancer Early Detection Blood Test from CCGA Study

May 31, 2019

GRAIL Announces Promising New Data with Early Detection Blood Test to be Presented at 2019 American Society of Clinical Oncology Annual Meeting

May 15, 2019

GRAIL Announces Significant Progress with Multi-Cancer Early Detection Test Including FDA Breakthrough Device Designation

May 13, 2019

GRAIL Announces Appointment of Catherine Friedman as Chair of GRAIL Board

December 10, 2018

GRAIL Announces Plans to Initiate SUMMIT Study to Support Development of Blood Test for Early Cancer Detection

December 3, 2018

Striving for Earlier Cancer Detection

November 5, 2018

GRAIL to Present New Data from the Circulating Cell-free Genome Atlas (CCGA) Study at the European Society for Medical Oncology (ESMO) 2018 Congress

October 19, 2018

GRAIL Announces Appointment of Renée Galá as Chief Financial Officer

October 4, 2018

GRAIL Announces Appointment of Hal Barron and Hans Bishop to its Board of Directors

August 9, 2018

GRAIL Announces Appointment of Key Executives as Company Makes Continued Progress in Development of Early Detection Products

July 9, 2018

GRAIL Announces Data on Detection of Early-Stage Lung Cancers

June 2, 2018

GRAIL Announces $300 Million Raised in Oversubscribed Series C Financing

May 21, 2018

GRAIL to Present New Data from Circulating Cell-free Genome Atlas (CCGA) Study at 2018 American Society of Clinical Oncology Annual Meeting

May 16, 2018

GRAIL Announces Data from Prototype Blood Tests for Early Cancer Detection

April 17, 2018

GRAIL Announces Appointment of Jennifer Cook as Chief Executive Officer

December 14, 2017

GRAIL Appoints Chairman Bill Rastetter to Chief Executive Officer

August 2, 2017

GRAIL Announces Data From Early Research Analyzing its High-Intensity Sequencing Approach

June 3, 2017

GRAIL and Cirina Combine to Create Global Company Focused on Early Detection of Cancer

May 31, 2017

GRAIL Announces Board of Directors Appointments

May 4, 2017

GRAIL Initiates the STRIVE Study to Advance Development of Blood Tests to Detect Cancer Early

April 20, 2017

GRAIL Closes Over $900 Million Initial Investment in Series B Financing to Develop Blood Tests to Detect Cancer Early

March 1, 2017

GRAIL Plans to Raise in Excess of $1B in Series B Funding

January 5, 2017

GRAIL Announces Circulating Cell-free Genome Atlas (CCGA) Study as Foundation for Development of Blood Test to Detect Cancer Early

December 1, 2016

GRAIL Hires Google Executive Jeff Huber as CEO to Lead Development for Early Cancer Detection

February 10, 2016

Illumina Forms New Company to Enable Early Cancer Detection via Blood-Based Screening

January 10, 2016